Publication|Articles|September 24, 2025
Supplements and Featured Publications
- Long-Acting Injectable Administration In Schizophrenia With Insights From Genoa Healthcare® Pharmacy
Optimizing Long-Acting Injectable Administration for Patients Living With Schizophrenia
Listen
0:00 / 0:00
Advertisement
This educational resource was sponsored by Johnson & Johnson.
In this educational resource, experts from a pharmacy and hospital provide an overview of their respective long-acting injectable antipsychotic programs, which are designed to help improve access and adherence to medications for people living with a severe and persistent mental illness like schizophrenia.
Articles in this issue
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Older Adults Drive Hospitalizations, Costs in the US 2024-2025 Influenza Season
2
RSV Vaccination Effective in Older Adults, but Protection Declines Over Time
3
Discontinuing GLP-1s Before or Early in Pregnancy Tied to Weight Gain, Pregnancy Complications
4
Tapinarof Shows Strong Efficacy, Sleep Benefits in Pediatric AD Across Comorbidities: Druhan Howell, MD
5










































